Observation on the effective dose of remimazolam tosylate combined with low-dose esketamine in inhibiting the reaction of gastroscope insertion

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200058749

Enrollment

Unknown

Registered

2022-04-16

Start date

2022-05-01

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

Experimental group:Remimazolam combined with low-dose esketamine, change the remazolam dose

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing painless gastroscopy under general anesthesia; 2. American anesthesiologist association (ASA) anesthesia grade I or II; 3. Aged 18-60 years; 4. body mass index (BMI) 18.5 24kg/m2.

Exclusion criteria

Exclusion criteria: 1. Severe hypertension or diabetes; 2. Coronary heart disease; 3. Central nervous system diseases; 4. Pathological obesity/obstructive sleep apnea; 5. Allergies to the study drug; 6. Take benzodiazepines intermittently or for a long time within 2 months before admission; 7. Schizophrenia and severe depression; 8. Acute upper respiratory tract infection or asthma attack; 9. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
ED50;	—

Secondary

Measure	Time frame
ED95;adverse event rate;	—

Countries

China

Contacts

Public ContactYan Zhangjun

Zhuji People's Hospital

949153954@qq.oom+86 152 5752 5029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026